

# Partnering in Oral Health



Our goal is to discover and develop breakthroughs in animal health for diseases with significant unmet need. To achieve this, we're investing in cutting-edge science and technology to expand and accelerate our drug discovery for the next generation of treatments and preventive therapies. With a track record of converting research and development innovation into blockbuster products, our oral health pipeline builds on this legacy with an ambition to deliver innovative solutions in diseases with high unmet need such as periodontitis.

Collaborations with innovative and entrepreneurial partners are helping solve the biggest challenges in animal health. We believe that by working together we can bring critical diversity to innovation and accelerate the next wave of therapeutics that will transform the health and well-being of animals now and in generations to come.


## Partnering Interests

Actively pursuing new partnerships in our research focus areas and open to a variety of partnership models to explore:

- Easily-administered treatments to prevent/reduce canine halitosis and gingivitis
- Easily-administered treatments to prevent/reduce calculus build-up and bone/tooth loss in dogs
- Treatments for feline odontoclastic resorptive lesions
- Treatments for chronic feline gingivostomatitis.

## Research Focus

- Targeting high, unmet needs to provide safe and effective treatment for animals with dental disease
- Non-surgical solutions for periodontitis.



## Collaboration Driving Innovation


- Growing our global community of innovation partners
- Multiple collaborations advancing new therapies
- Long-term partnerships for the next generation of breakthroughs

## Meet the Team




**Kate Christmas**  
[kathryn.christmas@boehringer-ingelheim.com](mailto:kathryn.christmas@boehringer-ingelheim.com)

### Investing in Animal Health Innovation




>€450 million

R&D for new medicines




Global

R&D presence in Europe, N. America, Asia



~1,200


staff in R&D facilities worldwide




>250

innovation collaborations

### Leveraging synergies with Human Pharma



Exchanging scientific knowledge and expertise



Access to data, models and back-up compounds

